HF
CTMX icon

HRT Financial’s CytomX Therapeutics CTMX Stock Holding History

HRT Financial’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-71,867
Closed -$306K – 3943
2025
Q4 		$306K Buy
+71,867
New +$273K ﹤0.01% 2362
2025
Q1 		– Sell
-110,242
Closed -$113K – 2649
2024
Q4 		$113K Buy
110,242
+83,402
+311% +$89.7K ﹤0.01% 2038
2024
Q3 		$31K Buy
+26,840
New +$34.1K ﹤0.01% 2153
2024
Q2 		– Sell
-16,831
Closed -$36K – 2363
2024
Q1 		$36K Buy
+16,831
New +$31.1K ﹤0.01% 1967
2022
Q2 		– Sell
-68,259
Closed -$182K – 3048
2022
Q1 		$182K Sell
68,259
-75,901
-53% -$291K ﹤0.01% 2515
2021
Q4 		$624K Sell
144,160
-5,016
-3% -$29.4K ﹤0.01% 1586
2021
Q3 		$759K Buy
+149,176
New +$799K ﹤0.01% 1563
2021
Q1 		– Sell
-27,640
Closed -$181K – 2755
2020
Q4 		$181K Buy
27,640
+5,382
+24% +$38.4K ﹤0.01% 1514
2020
Q3 		$148K Buy
+22,258
New +$165K ﹤0.01% 1447
2020
Q1 		– Sell
-18,478
Closed -$153K – 866
2019
Q4 		$153K Buy
+18,478
New +$125K 0.01% 980

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HRT Financial's CTMX Position: Q1 2026 in Review

HRT Financial sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 71,867 shares — an estimated $306K sold.

HRT Financial first reported a position in CTMX in Q4 2019 and held it in 10 quarters. The position peaked at $759K in Q3 2021. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • HRT Financial reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • HRT Financial sold 71,867 CytomX Therapeutics shares in Q1 2026, an estimated $306K.
  • HRT Financial first reported a position in CytomX Therapeutics in Q4 2019 and held it in 10 quarters.
  • HRT Financial's CytomX Therapeutics position peaked at $759K in Q3 2021.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.